Selected research
Industry Research
Drug Stability Testing Industry Research Report 2026
Market perspective
The global Drug Stability Testing market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Drug Stability Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Drug Stability Testing market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Drug Stability Testing market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Drug Stability Testing include Q Laboratories, Eurofins BioPharma, Intertek Group, Labcorp, Charles River Laboratories, SGS, Pacific BioLabs, Element Materials Technology and Catalent, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Drug Stability Testing market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Drug Stability Testing.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Drug Stability Testing Market by Company
Q Laboratories
Eurofins BioPharma
Intertek Group
Labcorp
Charles River Laboratories
SGS
Pacific BioLabs
Element Materials Technology
Catalent
Nelson Labs
PerkinElmer
BioProcess International
Ardena
Selvita
Alcami
Drug Stability Testing Segment by Type
Drug Substances
Finished Drug
Drug Stability Testing Segment by Application
Pharmaceutical Companies
Biopharmaceutical and Vaccine Companies
Advanced Therapies Companies
Others
Drug Stability Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Stability Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drug Stability Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Stability Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Drug Stability Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Drug Substances
- Finished Drug
Applications
- Pharmaceutical Companies
- Biopharmaceutical and Vaccine Companies
- Advanced Therapies Companies
- Others
Companies covered
- Q Laboratories
- Eurofins BioPharma
- Intertek Group
- Labcorp
- Charles River Laboratories
- SGS
- Pacific BioLabs
- Element Materials Technology
- Catalent
- Nelson Labs
- PerkinElmer
- BioProcess International
- Ardena
- Selvita
- Alcami
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Drug Stability Testing by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Drug Substances
- 2.2.3 Finished Drug
- 2.3 Drug Stability Testing by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical Companies
- 2.3.3 Biopharmaceutical and Vaccine Companies
- 2.3.4 Advanced Therapies Companies
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Drug Stability Testing Breakdown Data by Type
- 3.1 Global Drug Stability Testing Historic Market Size by Type (2021-2026)
- 3.2 Global Drug Stability Testing Forecasted Market Size by Type (2027-2032)
4 Drug Stability Testing Breakdown Data by Application
- 4.1 Global Drug Stability Testing Historic Market Size by Application (2021-2026)
- 4.2 Global Drug Stability Testing Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Drug Stability Testing Market Perspective (2021-2032)
- 5.2 Global Drug Stability Testing Growth Trends by Region
- 5.2.1 Global Drug Stability Testing Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Drug Stability Testing Historic Market Size by Region (2021-2026)
- 5.2.3 Drug Stability Testing Forecasted Market Size by Region (2027-2032)
- 5.3 Drug Stability Testing Market Dynamics
- 5.3.1 Drug Stability Testing Industry Trends
- 5.3.2 Drug Stability Testing Market Drivers
- 5.3.3 Drug Stability Testing Market Challenges
- 5.3.4 Drug Stability Testing Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Drug Stability Testing Players by Revenue
- 6.1.1 Global Top Drug Stability Testing Players by Revenue (2021-2026)
- 6.1.2 Global Drug Stability Testing Revenue Market Share by Players (2021-2026)
- 6.2 Global Drug Stability Testing Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Drug Stability Testing Head Office and Area Served
- 6.4 Global Drug Stability Testing Players, Product Type & Application
- 6.5 Global Drug Stability Testing Manufacturers Established Date
- 6.6 Global Drug Stability Testing Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Drug Stability Testing Market Size (2021-2032)
- 7.2 North America Drug Stability Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Drug Stability Testing Market Size by Country (2021-2026)
- 7.4 North America Drug Stability Testing Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Drug Stability Testing Market Size (2021-2032)
- 8.2 Europe Drug Stability Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Drug Stability Testing Market Size by Country (2021-2026)
- 8.4 Europe Drug Stability Testing Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Drug Stability Testing Market Size (2021-2032)
- 9.2 Asia-Pacific Drug Stability Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Drug Stability Testing Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Drug Stability Testing Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Drug Stability Testing Market Size (2021-2032)
- 10.2 South America Drug Stability Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Drug Stability Testing Market Size by Country (2021-2026)
- 10.4 South America Drug Stability Testing Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Drug Stability Testing Market Size (2021-2032)
- 11.2 Middle East & Africa Drug Stability Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Drug Stability Testing Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Drug Stability Testing Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Q Laboratories
- 12.1.1 Q Laboratories Company Information
- 12.1.2 Q Laboratories Business Overview
- 12.1.3 Q Laboratories Revenue in Drug Stability Testing Business (2021-2026)
- 12.1.4 Q Laboratories Drug Stability Testing Product Portfolio
- 12.1.5 Q Laboratories Recent Developments
- 12.2 Eurofins BioPharma
- 12.2.1 Eurofins BioPharma Company Information
- 12.2.2 Eurofins BioPharma Business Overview
- 12.2.3 Eurofins BioPharma Revenue in Drug Stability Testing Business (2021-2026)
- 12.2.4 Eurofins BioPharma Drug Stability Testing Product Portfolio
- 12.2.5 Eurofins BioPharma Recent Developments
- 12.3 Intertek Group
- 12.3.1 Intertek Group Company Information
- 12.3.2 Intertek Group Business Overview
- 12.3.3 Intertek Group Revenue in Drug Stability Testing Business (2021-2026)
- 12.3.4 Intertek Group Drug Stability Testing Product Portfolio
- 12.3.5 Intertek Group Recent Developments
- 12.4 Labcorp
- 12.4.1 Labcorp Company Information
- 12.4.2 Labcorp Business Overview
- 12.4.3 Labcorp Revenue in Drug Stability Testing Business (2021-2026)
- 12.4.4 Labcorp Drug Stability Testing Product Portfolio
- 12.4.5 Labcorp Recent Developments
- 12.5 Charles River Laboratories
- 12.5.1 Charles River Laboratories Company Information
- 12.5.2 Charles River Laboratories Business Overview
- 12.5.3 Charles River Laboratories Revenue in Drug Stability Testing Business (2021-2026)
- 12.5.4 Charles River Laboratories Drug Stability Testing Product Portfolio
- 12.5.5 Charles River Laboratories Recent Developments
- 12.6 SGS
- 12.6.1 SGS Company Information
- 12.6.2 SGS Business Overview
- 12.6.3 SGS Revenue in Drug Stability Testing Business (2021-2026)
- 12.6.4 SGS Drug Stability Testing Product Portfolio
- 12.6.5 SGS Recent Developments
- 12.7 Pacific BioLabs
- 12.7.1 Pacific BioLabs Company Information
- 12.7.2 Pacific BioLabs Business Overview
- 12.7.3 Pacific BioLabs Revenue in Drug Stability Testing Business (2021-2026)
- 12.7.4 Pacific BioLabs Drug Stability Testing Product Portfolio
- 12.7.5 Pacific BioLabs Recent Developments
- 12.8 Element Materials Technology
- 12.8.1 Element Materials Technology Company Information
- 12.8.2 Element Materials Technology Business Overview
- 12.8.3 Element Materials Technology Revenue in Drug Stability Testing Business (2021-2026)
- 12.8.4 Element Materials Technology Drug Stability Testing Product Portfolio
- 12.8.5 Element Materials Technology Recent Developments
- 12.9 Catalent
- 12.9.1 Catalent Company Information
- 12.9.2 Catalent Business Overview
- 12.9.3 Catalent Revenue in Drug Stability Testing Business (2021-2026)
- 12.9.4 Catalent Drug Stability Testing Product Portfolio
- 12.9.5 Catalent Recent Developments
- 12.10 Nelson Labs
- 12.10.1 Nelson Labs Company Information
- 12.10.2 Nelson Labs Business Overview
- 12.10.3 Nelson Labs Revenue in Drug Stability Testing Business (2021-2026)
- 12.10.4 Nelson Labs Drug Stability Testing Product Portfolio
- 12.10.5 Nelson Labs Recent Developments
- 12.11 PerkinElmer
- 12.11.1 PerkinElmer Company Information
- 12.11.2 PerkinElmer Business Overview
- 12.11.3 PerkinElmer Revenue in Drug Stability Testing Business (2021-2026)
- 12.11.4 PerkinElmer Drug Stability Testing Product Portfolio
- 12.11.5 PerkinElmer Recent Developments
- 12.12 BioProcess International
- 12.12.1 BioProcess International Company Information
- 12.12.2 BioProcess International Business Overview
- 12.12.3 BioProcess International Revenue in Drug Stability Testing Business (2021-2026)
- 12.12.4 BioProcess International Drug Stability Testing Product Portfolio
- 12.12.5 BioProcess International Recent Developments
- 12.13 Ardena
- 12.13.1 Ardena Company Information
- 12.13.2 Ardena Business Overview
- 12.13.3 Ardena Revenue in Drug Stability Testing Business (2021-2026)
- 12.13.4 Ardena Drug Stability Testing Product Portfolio
- 12.13.5 Ardena Recent Developments
- 12.14 Selvita
- 12.14.1 Selvita Company Information
- 12.14.2 Selvita Business Overview
- 12.14.3 Selvita Revenue in Drug Stability Testing Business (2021-2026)
- 12.14.4 Selvita Drug Stability Testing Product Portfolio
- 12.14.5 Selvita Recent Developments
- 12.15 Alcami
- 12.15.1 Alcami Company Information
- 12.15.2 Alcami Business Overview
- 12.15.3 Alcami Revenue in Drug Stability Testing Business (2021-2026)
- 12.15.4 Alcami Drug Stability Testing Product Portfolio
- 12.15.5 Alcami Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst